| Hematology | ||||||
| No. | Study Title | Principle Investigator | Sponsor | Type | Recruiting | Study status |
| 1 | REACH 3 study: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation. | Dr. Husam Abu Jazar | Novartis | Clinical Trial | No | Ongoing |
| 2 | Safety and Efficacy of Dasatinib 50 mg in First Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia. | Dr. Kamal Al-Rabi | Hikma | Clinical Trial | Yes | Ongoing |
| 3 | A phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AML. | Dr. Mayada Abu Shanab | Novartis | Clinical Trial | No | Pending |